IOL Chemicals & Pharmaceuticals Ltd Forensic Report - SOIC x StockScans Report

as of Aug 2026

IOL Chemicals & Pharmaceuticals presents a fundamentally clean statutory record: seven years of unqualified audit opinions, no fraud or wilful default, and a balance sheet free of promoter pledges. The story is dominated by two things: a promoter family that controls the board and sets its own pay despite repeated institutional shareholder dissent, and a revenue-recognition risk that has stayed on the auditor's Key Audit Matter list for five years running while receivables have grown faster than sales.

Key findings

  1. Promoter family dominates the board and sets escalating pay, while institutions repeatedly vote no Major - Managing Director Varinder Gupta's remuneration rose 141% over six years to ₹11.58 crore in FY2026, and his two sons hold executive board positions, bringing combined family pay to ₹16.81 crore. The board can raise Varinder Gupta's and Abhiraj Gupta's pay by up to 50% a year, and Vikas Gupta's by up to 25% a year, and can pay full remuneration even in loss years without further shareholder approval. Public institutional shareholders voted 85.93% against the re-appointment of Vikas Gupta in August 2022, 80.10% against the variation in his terms in May 2023, and 89.76% against his re-appointment again in August 2024.
  2. An ₹11.21 crore exceptional charge for revised labour-code gratuity was booked in FY26, and an unlisted overseas investment is carried at cost Minor - The company recognised an exceptional item of ₹11.21 crore in the December 2025 quarter after the Government of India notified four Labour Codes on 21 November 2025 with immediate effect. An investment in an unlisted overseas entity is carried at its historical cost of ₹17.41 crore; an independent valuer assessed fair value, and management concluded that cost approximates fair value.
  3. The group has expanded from zero subsidiaries in FY20 to three in FY26, with entities incorporated and closed across five jurisdictions Minor - Three wholly owned subsidiaries were incorporated in FY23, IOL Global Limited (UK) was closed in FY24, and IOL Life Sciences Limited was struck off effective 1 April 2026. IOL Pharmaxis UK Limited was incorporated on 16 October 2025, had yet to commence operations as of 31 March 2026, and was excluded from consolidation.
  4. Two minor procedural fines from stock exchanges in FY25 and FY26, with no other regulatory actions over seven years Minor - BSE imposed a penalty of ₹2,000 for filing a shareholding pattern one day late in FY26. In FY25, BSE and NSE each fined the company ₹1,89,000 for a delay in filling the women independent director vacancy and in Nomination and Remuneration Committee composition; the fine was paid on 20 March 2025 and compliance was achieved on 28 October 2024.
  5. Clean audit opinions across all years, no fraud, no wilful default, and no fund-diversion flags Clean - Statutory auditors issued unqualified opinions on standalone and consolidated financial statements for every year from FY2019-20 through FY2025-26. No fraud was reported under Section 143(12) in any year, and CARO clauses confirm no benami proceedings, no wilful default, and no fund diversion in any year from FY21-22 through FY25-26.

What to watch

Bottom line: This is a disclosed and audited record with a genuinely clean statutory core. The risk is one of governance: a promoter family that controls the board, sets its own pay with built-in escalators, and has been repeatedly opposed by institutional shareholders on appointments, while the auditor has flagged revenue recognition as a Key Audit Matter for five consecutive years. Watch the customs appeal and whether the greenfield funding plan holds without debt.